Dietary and pharmaceutical uses of methyl-sulfonylmethane and compositions comprising it

• US 4,559,329 A
• Filed: 04/17/1984
• Issued: 12/17/1985
• Est. Priority Date: 09/14/1982
• Status: Expired due to Term

• Current Assignee: Cardinal Associates, Inc. (Balchem Corporation)
• Original Assignee: Robert J. Herschler
• Inventors: Herschler, Robert J.
• Primary Examiner(s): FRIEDMAN, STANLEY
• Application Number:
  US06/601,771
• Time in Patent Office: 609 Days
• Field of Search: 424/337, 424/230, 514/164, 514/199, 514/357, 514/372, 514/420, 514/474, 514/557, 514/652, 514/708
• US Class Current: 514/164
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/10 Sulfides; Sulfoxides; Sulfones
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 9/1688 resulting in pure drug agglomerate optionally containing up to 5% of excipient
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methylsulfonylmethane (CH₃ SO₂ CH₃) administered orally is effective in ameliorating the symptoms of gastrointestinal upset, e.g., produced by the ingestion of aspirin and other pharmaceuticals, and of allergic reactions. Oral compositions containing a mixture of such a pharmaceutical and methylsulfonylmethane are useful in avoiding the gastrointestinal upset which otherwise occurs when ingesting the former.

Claims

1. A pharmaceutical composition adapted for oral ingestion comprising a mixture of (a) gastrointestinal upset-promoting but otherwise physiologically acceptable pharmaceutically-active agent selected from the group consisting of analgesics, anti-neoplastic agents, anti-inflammatory agents, cardiovascular agents, antibiotics and other chemotherapeutants for microbial diseases, and (b) a gastrointestinal upset-ameliorating effective amount from about 100 to 1,000 mg of methylsulfonymethane.

2. A composition according to claim 1, in the form of tablets, capsules, dragees or pills.

3. A composition according to claim 1, wherein the composition contains from about 250 to 500 mg of methylsulfonymethane per unit dosage.

4. A composition according to claim 1, wherein the pharmaceutically-active agent is an analgesic.

5. A composition according to claim 1, wherein the pharmaceutically-active agent is an aspirin.

6. A flowable powder adapted for compression into orally ingestible tablets, wherein the powder particles consist essentially of a pharmaceutically orally active agent selected from the group consisting of analgesics, anti-neoplastic agents, anti-inflammatory agents, cardiovascular agents, antibiotics and other chemotherapeutants for microbial diseases, suspended or dissolved in an amount from about 100 to 1,000 mg of methylsulfonylmethane effective to improve the flow characteristics of the former in powder form.

7. The flowable powder according to claim 6 wherein the pharmaceutically-active compound is dissolved in the methylsulfonylmethane.

8. The flowable powder according to claim 6 wherein the powder particles are substantially anhydrous and the pharmaceutically-active agent is unstable in the presence of moisture.

9. A pharmaceutical composition in granule or tablet form adapted for oral ingestion and comprising a pharmaceutically orally-active agent selected from the group consisting of analgesics, anti-neoplastic agents, anti-inflammatory agents, cardiovascular agents, antibiotics and other chemotherapeutants for microbial diseases, and a granulating or tableting adjuvant, respectively, consisiting predominantly of from 100 to 1,000 mg of methylsulfonylmethane.

10. The pharmaceutical composition according to claim 9 in tablet form.

11. The pharmaceutical composition according to claim 9 in granule form and contains from 0.25 to 2% colloidal silica.